Aim: The article has been selected due to the need to determine the legal basis for the consolidation of entrepreneurs on the pharmaceutical market and to identify the difference from the common pattern established by the regulations set forth in the Competition and Consumer Protection Act dated 16 February 2007. The selection of an enactment (the Competition and Consumer Protection Act or the Pharmaceutical Law Act) as the appropriate basis for ruling shapes the legal status of an entrepreneur on the pharmaceutical market, in particular with respect to selecting specific remedies.
Introduction
The fair competition principle, which is one of the essential business principles, has been 
Uniqueness of the Pharmaceutical Market
First, it is worth noting that the term "pharmaceutical market" is a complex term with a concept of a "medicinal product" playing an important role as its component.
1 According to the elementary division of the pharmaceutical market, 2 regulated by the Pharmaceutical Law, the sector is divided into the medicinal product manufacturing sector and the medicinal product trading sector, further divided into the wholesale medicinal product sector 3 and the retail medicinal product sector.
4
There is no doubt that the pharmaceutical sector is characterised by very strict administrative and legal control of economic behaviour related to the sphere of starting, running and closing a business (Stankiewicz 2014: 77; Podleś 2011: 11 ff.) , manifesting itself predominantly in the requirement to obtain a respective administrative decision. 5 In the Pharmaceutical Law, the restriction on the freedom of enterprise is justified essentially with the need to protect the public health, which boils down to "the important public interest" (mentioned in the provisions of the 2 R. Stankiewicz defines the "pharmaceutical market" as a "system of relations between entities participating in manufacturing a medicinal product, entities involved in its wholesale and retail sale and consumers" and differentiates it from the "pharmaceutical sector", identifying the latter solely with the medicinal product manufacturing segment (Stankiewicz 2014: 77, 88) . It seems that M. Krekora's use of the notion of "pharmaceutical market" is boarder and it is referred to the "medicinal product market" (Krekora 2006: 15 ff. ECR p. II-2969).Moreover, this phenomenon is inseparably related with another feature of the pharmaceutical sector which is demand for medicinal product since the decision is made by the doctor and not by the patient, in particular where prescription-only medicinal products are concerned(Announcement of the Commission -Executive Summary of the Pharmaceutical Sector Audit Report: 9). For this reason, we may recognise some non-price related competition elements (the main pressure is put on the preferred course of treatment) as the price of a medicinal product is not the decisive element, i.e. predominantly affecting the decision to buy a medicinal product.
A concise presentation of the key features of the pharmaceutical sector was needed and essential for the sake of clarity and understanding author's analyses presented below, concerning the mechanisms of entrepreneurs' concentration on the pharmaceutical market.
Concentration of Entrepreneurs on the Pharmaceutical Market
The fundamental act of law containing provisions related to the concentration of entrepreneurs and its control is the CCPA. In the provisions of Article 1, the legislator, defining the subject-related scope of its applicability, stated that it governs "the rules and procedure for counteracting (.. It is worth noting that anti-concentration restrictions on the pharmaceutical market were introduced to the national legislature less than one year from adopting the original version of the Pharmaceutical Law.
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According to the provisions of Article 99 par. 3 of the Pharmaceutical Law, "the permit (...)
shall not be issued when the applicant: 1) runs or has applied for permit to run medicinal product wholesale or act as an agent in selling medical devices or b) runs more than 1% of retail pharmacies on the territory of a region or entity which he controls, directly or indirectly, in particular subsidiaries defined in the CCPA, run jointly more than 1% of pharmacies in a region; 3) is a member of a capital group as defined in the CCPA, members of which run more than 1% of retail pharmacies in a region". The present status of the regulation governing the anti-competitive concentration in the Pharmaceutical Law is commonly criticised as failing to achieve the purposes for which it was adopted. In the doctrine, it is claimed that the legislator intended to prevent an excessive concentration of retail pharmacies in the hands of one entity (Skoczny 2015: 7; Krekora2012: 404-405 of the Pharmaceutical Law. The conclusion is consequent upon the argumentation that "the acquisition of shares (stock), resulting in exceeding the threshold, causes a change in the factual and legal status. Entrepreneurs who, as a result of buying shares (stock), combined their efforts as a group of related entities ceased to meet conditions for receiving a permit to run retail pharmacies and, consequently, run a business specified in the permit".
In the light of the above, it must considered that the provisions of the CCPA -being a general law -will be applied further on, as the correct substantive basis for decisions on anticompetitive concentration of entrepreneurs on the pharmaceutical market. In consequence, it is assumed that the preventive obligation to notify the intention to concentrate is not dependent on the sector of the anticipated concentration (Kohutek 2008: 448) . Consequently, a general In spite of the above-described, noticeable differences, one should recognise the identity of objective the legislator wanted to achieve, when introducing the abovediscussed provision to the Pharmaceutical Law and CCPA (protection against anti-competitive concentration). 
